DexCom Inc (DXCM)

Currency in USD
72.47
+1.24(+1.74%)
Closed·
72.470.00(0.00%)
·
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
71.6073.69
52 wk Range
54.1189.98
Key Statistics
Prev. Close
71.23
Open
72.61
Day's Range
71.6-73.69
52 wk Range
54.11-89.98
Volume
8.57M
Average Vol. (3m)
5.46M
1-Year Change
-9.4125%
Book Value / Share
7.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
85.21
Upside
+17.58%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

DexCom Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

24 Buy
3 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 85.21
(+17.58% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
KeyBanc
Buy88.00+21.43%75.00MaintainJun 15, 2026
TD Cowen
Buy95.00+31.09%75.00MaintainJun 10, 2026
Mizuho
Buy85.00+17.29%75.00MaintainJun 09, 2026
Stifel
Buy90.00+24.19%85.00MaintainJun 05, 2026
Citi
Buy84.00+15.91%79.00MaintainMay 28, 2026

DexCom Inc SWOT Analysis


Quality vs. Margins
Discover how Dexcom's quality enhancement initiatives create near-term profitability pressures while potentially building long-term competitive advantages
Competitive Battlefield
Intensifying rivalry in Type 1 and intensive Type 2 diabetes markets threatens market share as new entrants and established players introduce alternative solutions
Analyst Targets
Price targets range from $71 to $80, reflecting mixed analyst sentiment on the company's ability to navigate competitive pressures and margin challenges
Q4 Performance Shines
Dexcom exceeded Q4 sales and earnings expectations, demonstrating operational strength in diabetes management technology despite market uncertainties
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q1/2026

  • DexCom Q1 2026 EPS of $0.56 beat estimates by 19%; revenue of $1.19B exceeded forecasts by 1.71%, driving 3.41% stock gain to $57.99.
  • Revenue rose 15% YoY with international sales surging 26% to $360M; U.S. sales increased 11% to $832M on strong CGM system demand.
  • Gross margin expanded to 63.5% from 57.5% YoY; operating income jumped to 22.2% of revenue vs. 13.8% in Q1 2025.
  • Company raised FY2026 operating margin guidance to 23%-23.5% and EBITDA margin to 31%-31.5%; expects revenue of $5.16B-$5.25B.
  • CEO cited sustainable growth and margin expansion; risks include geopolitical cost pressures, competition, and potential supply chain disruptions.
Last Updated: 04/30/2026, 05:54 PM
Read Full Transcript
DexCom investor slides for Q1/2026
DexCom Q1 2026 slides
Last Update: Apr 30, 2026
See full investor slides

Earnings

Latest Release
Apr 30, 2026
EPS / Forecast
0.56 / 0.47
Revenue / Forecast
1.19B / 1.17B
EPS Revisions
Last 90 days

DXCM Income Statement

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
30.1x22.0x−0.4x
PEG Ratio
0.40−0.800.00
Price / Book
9.5x2.3x2.6x
Price / LTM Sales
5.8x2.7x3.0x
Upside (Analyst Target)
17.3%52.3%58.1%
Fair Value Upside
Unlock5.3%8.2%Unlock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
213.06M55.21%15.44B
Other Institutional Investors
168.40M43.64%12.20B
Public Companies & Retail Investors
4.42M1.15%320.27M
Total
385.87M100.00%27.96B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.09%38,928,0482,821,116
Vanguard Capital Management, LLC6.48%25,020,9611,813,269

People Also Watch

850.00
LITE
-2.30%
185.00
SPCX
-3.56%
274.06
CEG
+2.58%
1,133.99
MU
+8.70%
210.69
NVDA
+2.95%

FAQ

What Is the DexCom (DXCM) Stock Price Today?

The DexCom stock price today is 72.47 USD.

What Stock Exchange Does DexCom Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for DexCom?

The stock symbol for DexCom is "DXCM."

What Is the DexCom Market Cap?

As of today, DexCom market cap is 27.96B USD.

What Is DexCom's Earnings Per Share (TTM)?

The DexCom EPS (TTM) is 2.34.

When Is the Next DexCom Earnings Date?

DexCom will release its next earnings report on Jul 23, 2026.

From a Technical Analysis Perspective, Is DXCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times.

How Many Employees Does DexCom Have?

DexCom has 11050 employees.

What is the current trading status of DexCom (DXCM)?

As of Jun 22, 2026, DexCom (DXCM) is trading at a price of 72.47 USD, with a previous close of 71.23 USD. The stock has fluctuated within a day range of 71.60 USD to 73.69 USD, while its 52-week range spans from 54.11 USD to 89.98 USD.

What Is DexCom (DXCM) Price Target According to Analysts?

The average 12-month price target for DexCom is 85.21 USD, with a high estimate of 112 USD and a low estimate of 65 USD. 24 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +17.58% Upside potential.

What Is the DXCM Premarket Price?

DXCM's last pre-market stock price is 72.78 USD. The pre-market share volume is 8,570,000.00, and the stock has decreased by 0.31, or 0.43%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.